title: Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?
abstract: OBJECTIVE
  Immediately after stent/scaffold implantation, quantitative coronary angiography (QCA) in comparison to optical coherence tomography (OCT) more severely underestimates the lumen diameter (LD) in Absorb than in XIENCE. This OCT-QCA discrepancy has not been evaluated at long-term follow-up. The present study aimed to assess the accuracy of QCA with reference to OCT in Absorb as compared to XIENCE.
  
  
  RESULTS
  We assessed two-year QCA and OCT in the ABSORB Japan randomised trial (Absorb n=87, XIENCE n=44). The accuracy of QCA parameters was assessed with reference to OCT measurements. OCT-QCA luminal dimensions were compared in matched cross-sections at both edges of the scaffolds (n=127) and stents (n=78). OCT-QCA late lumen loss (LLL) was also assessed using the Bland-Altman method. The systematic error of LD on QCA in Absorb was -0.092 mm (relative difference -3.3%) with a random error of 0.473 mm, whereas in XIENCE the systematic error was -0.018 mm (-0.5%) with a random error of 0.477 mm. These OCT-QCA discrepancies did not differ between Absorb and XIENCE (p=0.275) at two-year follow-up. QCA tended to underestimate LLL more in Absorb than in XIENCE (QCA-LLL minus OCT-LLL: -0.180±0.308 mm vs. -0.058±0.322 mm, p=0.058) at two-year follow-up, although this comparison was not statistically powered.
  
  
  CONCLUSIONS
  The two-year dimensional measurements on QCA had minor and insignificant systematic errors between both devices. A discrepancy between QCA-LLL and OCT-LLL would raise a question as to whether this parameter is appropriate for the comparative assessment of device performance.
authors.affiliation: Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Sotomi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Onuma
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Taku
authors.initials: T
authors.lastname: Asano
authors.forename: Yuki
authors.initials: Y
authors.lastname: Katagiri
authors.forename: Erhan
authors.initials: E
authors.lastname: Tenekecioglu
authors.forename: Hans
authors.initials: H
authors.lastname: Jonker
authors.forename: Jouke
authors.initials: J
authors.lastname: Dijkstra
authors.forename: Robbert J
authors.initials: RJ
authors.lastname: de Winter
authors.forename: Joanna J
authors.initials: JJ
authors.lastname: Wykrzykowska
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Ken
authors.initials: K
authors.lastname: Kozuma
authors.forename: Kengo
authors.initials: K
authors.lastname: Tanabe
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
mesh_terms: D020341:Absorbable Implants; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002857:Chromium; D003035:Cobalt; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation; D020123:Sirolimus / Q000627:therapeutic use
chemical_list: D002317:Cardiovascular Agents; D002857:Chromium; D003035:Cobalt; D000068338:Everolimus; D020123:Sirolimus